View Financial HealthACME Laboratories 배당 및 자사주 매입배당 기준 점검 4/6ACME Laboratories 수익으로 충분히 충당되는 현재 수익률 4.23% 보유한 배당금 지급 회사입니다.핵심 정보4.2%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률-0.5%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향28%최근 배당 및 자사주 매입 업데이트공고 • Oct 29The ACME Laboratories Ltd. announces Annual dividend, payable on January 21, 2026The ACME Laboratories Ltd. announced Annual dividend of BDT 3.5000 per share payable on January 21, 2026, ex-date on November 19, 2025 and record date on November 18, 2025.Upcoming Dividend • Nov 14Upcoming dividend of ৳3.50 per shareEligible shareholders must have bought the stock before 21 November 2024. Payment date: 22 January 2025. Payout ratio is a comfortable 29% but the company is not cash flow positive. Trailing yield: 4.5%. Within top quartile of Bangladeshi dividend payers (4.5%). Higher than average of industry peers (3.6%).Declared Dividend • Oct 30Dividend of ৳3.50 announcedShareholders will receive a dividend of ৳3.50. Ex-date: 21st November 2024 Payment date: 22nd January 2025 Dividend yield will be 4.6%, which is higher than the industry average of 2.5%. Sustainability & Growth Dividend is covered by earnings (29% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 86 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 12% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Upcoming Dividend • Nov 18Upcoming dividend of ৳3.30 per share at 3.5% yieldEligible shareholders must have bought the stock before 23 November 2023. Payment date: 17 January 2024. Payout ratio is a comfortable 29% but the company is not cash flow positive. Trailing yield: 3.5%. Within top quartile of Bangladeshi dividend payers (3.4%). Higher than average of industry peers (2.5%).공고 • Oct 30The ACME Laboratories Ltd. Recommends Cash Dividend for the Year Ended June 30, 2023The Board of Directors of The ACME Laboratories Ltd. has recommended 33% cash dividend for the year ended June 30, 2023. Date of AGM December 18, 2023.Upcoming Dividend • Nov 16Upcoming dividend of ৳3.00 per shareEligible shareholders must have bought the stock before 21 November 2022. Payment date: 19 January 2023. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 3.5%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Higher than average of industry peers (2.5%).모든 업데이트 보기Recent updatesReported Earnings • Jun 02Third quarter 2026 earnings released: EPS: ৳3.30 (vs ৳2.81 in 3Q 2025)Third quarter 2026 results: EPS: ৳3.30 (up from ৳2.81 in 3Q 2025). Revenue: ৳10.4b (up 13% from 3Q 2025). Net income: ৳697.9m (up 17% from 3Q 2025). Profit margin: 6.7% (up from 6.4% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.공고 • Apr 24The ACME Laboratories Ltd. to Report Q3, 2026 Results on Apr 29, 2026The ACME Laboratories Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026공고 • Jan 25The ACME Laboratories Ltd. to Report Q2, 2026 Results on Jan 28, 2026The ACME Laboratories Ltd. announced that they will report Q2, 2026 results on Jan 28, 2026공고 • Nov 07The ACME Laboratories Ltd. to Report Q1, 2026 Results on Nov 12, 2025The ACME Laboratories Ltd. announced that they will report Q1, 2026 results on Nov 12, 2025공고 • Oct 29The ACME Laboratories Ltd. announces Annual dividend, payable on January 21, 2026The ACME Laboratories Ltd. announced Annual dividend of BDT 3.5000 per share payable on January 21, 2026, ex-date on November 19, 2025 and record date on November 18, 2025.공고 • Oct 28The ACME Laboratories Ltd., Annual General Meeting, Dec 22, 2025The ACME Laboratories Ltd., Annual General Meeting, Dec 22, 2025, at 11:30 Central Asia Standard Time.공고 • Oct 20The ACME Laboratories Ltd. to Report Fiscal Year 2025 Results on Oct 27, 2025The ACME Laboratories Ltd. announced that they will report fiscal year 2025 results on Oct 27, 2025공고 • Apr 23The ACME Laboratories Ltd. to Report Q3, 2025 Results on Apr 28, 2025The ACME Laboratories Ltd. announced that they will report Q3, 2025 results on Apr 28, 2025공고 • Jan 27The ACME Laboratories Ltd. to Report Q2, 2025 Results on Jan 29, 2025The ACME Laboratories Ltd. announced that they will report Q2, 2025 results on Jan 29, 2025Upcoming Dividend • Nov 14Upcoming dividend of ৳3.50 per shareEligible shareholders must have bought the stock before 21 November 2024. Payment date: 22 January 2025. Payout ratio is a comfortable 29% but the company is not cash flow positive. Trailing yield: 4.5%. Within top quartile of Bangladeshi dividend payers (4.5%). Higher than average of industry peers (3.6%).공고 • Nov 11The ACME Laboratories Ltd. to Report Q1, 2025 Results on Nov 13, 2024The ACME Laboratories Ltd. announced that they will report Q1, 2025 results on Nov 13, 2024Declared Dividend • Oct 30Dividend of ৳3.50 announcedShareholders will receive a dividend of ৳3.50. Ex-date: 21st November 2024 Payment date: 22nd January 2025 Dividend yield will be 4.6%, which is higher than the industry average of 2.5%. Sustainability & Growth Dividend is covered by earnings (29% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 86 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 12% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.공고 • Oct 29+ 1 more updateThe ACME Laboratories Ltd., Annual General Meeting, Dec 23, 2024The ACME Laboratories Ltd., Annual General Meeting, Dec 23, 2024, at 11:30 Central Asia Standard Time.공고 • Oct 17The ACME Laboratories Ltd. to Report Fiscal Year 2024 Results on Oct 27, 2024The ACME Laboratories Ltd. announced that they will report fiscal year 2024 results on Oct 27, 2024Reported Earnings • May 12Third quarter 2024 earnings released: EPS: ৳2.75 (vs ৳2.53 in 3Q 2023)Third quarter 2024 results: EPS: ৳2.75 (up from ৳2.53 in 3Q 2023). Revenue: ৳8.00b (up 22% from 3Q 2023). Net income: ৳582.3m (up 8.6% from 3Q 2023). Profit margin: 7.3% (down from 8.1% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.공고 • Apr 26The ACME Laboratories Ltd. to Report Q3, 2024 Results on Apr 29, 2024The ACME Laboratories Ltd. announced that they will report Q3, 2024 results on Apr 29, 2024공고 • Jan 25The ACME Laboratories Ltd. to Report Q2, 2024 Results on Jan 30, 2024The ACME Laboratories Ltd. announced that they will report Q2, 2024 results on Jan 30, 2024Upcoming Dividend • Nov 18Upcoming dividend of ৳3.30 per share at 3.5% yieldEligible shareholders must have bought the stock before 23 November 2023. Payment date: 17 January 2024. Payout ratio is a comfortable 29% but the company is not cash flow positive. Trailing yield: 3.5%. Within top quartile of Bangladeshi dividend payers (3.4%). Higher than average of industry peers (2.5%).공고 • Nov 08The ACME Laboratories Ltd. to Report Q1, 2024 Results on Nov 13, 2023The ACME Laboratories Ltd. announced that they will report Q1, 2024 results on Nov 13, 2023공고 • Oct 31The ACME Laboratories Ltd., Annual General Meeting, Dec 18, 2023The ACME Laboratories Ltd., Annual General Meeting, Dec 18, 2023, at 05:30 Coordinated Universal Time.공고 • Oct 30The ACME Laboratories Ltd. Recommends Cash Dividend for the Year Ended June 30, 2023The Board of Directors of The ACME Laboratories Ltd. has recommended 33% cash dividend for the year ended June 30, 2023. Date of AGM December 18, 2023.공고 • Oct 19The ACME Laboratories Ltd. to Report Fiscal Year 2023 Results on Oct 26, 2023The ACME Laboratories Ltd. announced that they will report fiscal year 2023 results on Oct 26, 2023Reported Earnings • May 16Third quarter 2023 earnings released: EPS: ৳2.53 (vs ৳2.38 in 3Q 2022)Third quarter 2023 results: EPS: ৳2.53 (up from ৳2.38 in 3Q 2022). Revenue: ৳6.59b (up 8.8% from 3Q 2022). Net income: ৳536.3m (up 6.5% from 3Q 2022). Profit margin: 8.1% (down from 8.3% in 3Q 2022). The decrease in margin was driven by higher expenses.Upcoming Dividend • Nov 16Upcoming dividend of ৳3.00 per shareEligible shareholders must have bought the stock before 21 November 2022. Payment date: 19 January 2023. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 3.5%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Higher than average of industry peers (2.5%).공고 • Oct 28The ACME Laboratories Ltd. Recommends Cash Dividend for the Year Ended June 30, 2022The Board of Directors of The ACME Laboratories Ltd. has recommended 30% cash dividend for the year ended June 30, 2022. Date of AGM: December 20, 2022.Reported Earnings • May 26Third quarter 2022 earnings released: EPS: ৳2.38 (vs ৳1.84 in 3Q 2021)Third quarter 2022 results: EPS: ৳2.38 (up from ৳1.84 in 3Q 2021). Revenue: ৳6.05b (up 16% from 3Q 2021). Net income: ৳503.7m (up 29% from 3Q 2021). Profit margin: 8.3% (up from 7.5% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 6% per year.Reported Earnings • Feb 05Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: EPS: ৳2.40 (up from ৳1.78 in 2Q 2021). Revenue: ৳5.67b (up 13% from 2Q 2021). Net income: ৳507.1m (up 35% from 2Q 2021). Profit margin: 8.9% (up from 7.5% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Upcoming Dividend • Nov 14Upcoming dividend of ৳2.50 per shareEligible shareholders must have bought the stock before 21 November 2021. Payment date: 25 January 2022. Trailing yield: 2.8%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.7%).Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improved over the past weekAfter last week's 16% share price gain to ৳108, the stock trades at a trailing P/E ratio of 15.2x. Average trailing P/E is 29x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 36% over the past three years.Valuation Update With 7 Day Price Move • Aug 09Investor sentiment improved over the past weekAfter last week's 15% share price gain to ৳88.10, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 13% over the past three years.Reported Earnings • Apr 30Third quarter 2021 earnings released: EPS ৳1.84 (vs ৳1.68 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ৳5.23b (up 9.8% from 3Q 2020). Net income: ৳390.2m (up 10% from 3Q 2020). Profit margin: 7.5% (up from 7.4% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Feb 22New 90-day low: ৳67.60The company is down 1.0% from its price of ৳68.00 on 24 November 2020. The Bangladeshi market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 18% over the same period.Reported Earnings • Jan 28Second quarter 2021 earnings released: EPS ৳1.78 (vs ৳1.77 in 2Q 2020)The company reported a mediocre second quarter result with weaker profit margins, although earnings were flat and revenues improved. Second quarter 2021 results: Revenue: ৳5.02b (up 7.7% from 2Q 2020). Net income: ৳377.1m (flat on 2Q 2020). Profit margin: 7.5% (down from 8.0% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Dec 28New 90-day high: ৳75.00The company is up 3.0% from its price of ৳72.70 on 29 September 2020. The Bangladeshi market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period.Is New 90 Day High Low • Nov 13New 90-day low: ৳68.00The company is down 1.0% from its price of ৳68.90 on 13 August 2020. The Bangladeshi market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period.공고 • Oct 08The ACME Laboratories Ltd. to Report Fiscal Year 2020 Results on Oct 14, 2020The ACME Laboratories Ltd. announced that they will report fiscal year 2020 results on Oct 14, 2020지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: ACMELAB 의 배당금 지급은 지난 10 년 동안 휘발성이었습니다.배당금 증가: ACMELAB 의 배당금 지급액은 지난 10 년 동안 증가하지 않았습니다.배당 수익률 vs 시장ACME Laboratories 배당 수익률 vs 시장ACMELAB의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ACMELAB)4.2%시장 하위 25% (BD)0.7%시장 상위 25% (BD)3.3%업계 평균 (Pharmaceuticals)3.7%분석가 예측 (ACMELAB) (최대 3년)n/a주목할만한 배당금: ACMELAB 의 배당금( 4.23% )은 BD 시장에서 배당금 지급자의 하위 25%( 0.72% )보다 높습니다.고배당: ACMELAB 의 배당금( 4.23% )은 BD 시장( 3.28% )주주 대상 이익 배당수익 보장: 합리적으로 낮은 지불 비율 ( 27.8% )로 ACMELAB 의 배당금 지급은 수익으로 충분히 충당됩니다.주주 현금 배당현금 흐름 범위: 현금 지급 비율 ( 23.4% )이 낮기 때문에 ACMELAB 의 배당금 지급은 현금 흐름으로 잘 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YBD 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/06 09:31종가2026/08/06 00:00수익2026/03/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스The ACME Laboratories Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공고 • Oct 29The ACME Laboratories Ltd. announces Annual dividend, payable on January 21, 2026The ACME Laboratories Ltd. announced Annual dividend of BDT 3.5000 per share payable on January 21, 2026, ex-date on November 19, 2025 and record date on November 18, 2025.
Upcoming Dividend • Nov 14Upcoming dividend of ৳3.50 per shareEligible shareholders must have bought the stock before 21 November 2024. Payment date: 22 January 2025. Payout ratio is a comfortable 29% but the company is not cash flow positive. Trailing yield: 4.5%. Within top quartile of Bangladeshi dividend payers (4.5%). Higher than average of industry peers (3.6%).
Declared Dividend • Oct 30Dividend of ৳3.50 announcedShareholders will receive a dividend of ৳3.50. Ex-date: 21st November 2024 Payment date: 22nd January 2025 Dividend yield will be 4.6%, which is higher than the industry average of 2.5%. Sustainability & Growth Dividend is covered by earnings (29% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 86 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 12% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Upcoming Dividend • Nov 18Upcoming dividend of ৳3.30 per share at 3.5% yieldEligible shareholders must have bought the stock before 23 November 2023. Payment date: 17 January 2024. Payout ratio is a comfortable 29% but the company is not cash flow positive. Trailing yield: 3.5%. Within top quartile of Bangladeshi dividend payers (3.4%). Higher than average of industry peers (2.5%).
공고 • Oct 30The ACME Laboratories Ltd. Recommends Cash Dividend for the Year Ended June 30, 2023The Board of Directors of The ACME Laboratories Ltd. has recommended 33% cash dividend for the year ended June 30, 2023. Date of AGM December 18, 2023.
Upcoming Dividend • Nov 16Upcoming dividend of ৳3.00 per shareEligible shareholders must have bought the stock before 21 November 2022. Payment date: 19 January 2023. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 3.5%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Higher than average of industry peers (2.5%).
Reported Earnings • Jun 02Third quarter 2026 earnings released: EPS: ৳3.30 (vs ৳2.81 in 3Q 2025)Third quarter 2026 results: EPS: ৳3.30 (up from ৳2.81 in 3Q 2025). Revenue: ৳10.4b (up 13% from 3Q 2025). Net income: ৳697.9m (up 17% from 3Q 2025). Profit margin: 6.7% (up from 6.4% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
공고 • Apr 24The ACME Laboratories Ltd. to Report Q3, 2026 Results on Apr 29, 2026The ACME Laboratories Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026
공고 • Jan 25The ACME Laboratories Ltd. to Report Q2, 2026 Results on Jan 28, 2026The ACME Laboratories Ltd. announced that they will report Q2, 2026 results on Jan 28, 2026
공고 • Nov 07The ACME Laboratories Ltd. to Report Q1, 2026 Results on Nov 12, 2025The ACME Laboratories Ltd. announced that they will report Q1, 2026 results on Nov 12, 2025
공고 • Oct 29The ACME Laboratories Ltd. announces Annual dividend, payable on January 21, 2026The ACME Laboratories Ltd. announced Annual dividend of BDT 3.5000 per share payable on January 21, 2026, ex-date on November 19, 2025 and record date on November 18, 2025.
공고 • Oct 28The ACME Laboratories Ltd., Annual General Meeting, Dec 22, 2025The ACME Laboratories Ltd., Annual General Meeting, Dec 22, 2025, at 11:30 Central Asia Standard Time.
공고 • Oct 20The ACME Laboratories Ltd. to Report Fiscal Year 2025 Results on Oct 27, 2025The ACME Laboratories Ltd. announced that they will report fiscal year 2025 results on Oct 27, 2025
공고 • Apr 23The ACME Laboratories Ltd. to Report Q3, 2025 Results on Apr 28, 2025The ACME Laboratories Ltd. announced that they will report Q3, 2025 results on Apr 28, 2025
공고 • Jan 27The ACME Laboratories Ltd. to Report Q2, 2025 Results on Jan 29, 2025The ACME Laboratories Ltd. announced that they will report Q2, 2025 results on Jan 29, 2025
Upcoming Dividend • Nov 14Upcoming dividend of ৳3.50 per shareEligible shareholders must have bought the stock before 21 November 2024. Payment date: 22 January 2025. Payout ratio is a comfortable 29% but the company is not cash flow positive. Trailing yield: 4.5%. Within top quartile of Bangladeshi dividend payers (4.5%). Higher than average of industry peers (3.6%).
공고 • Nov 11The ACME Laboratories Ltd. to Report Q1, 2025 Results on Nov 13, 2024The ACME Laboratories Ltd. announced that they will report Q1, 2025 results on Nov 13, 2024
Declared Dividend • Oct 30Dividend of ৳3.50 announcedShareholders will receive a dividend of ৳3.50. Ex-date: 21st November 2024 Payment date: 22nd January 2025 Dividend yield will be 4.6%, which is higher than the industry average of 2.5%. Sustainability & Growth Dividend is covered by earnings (29% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 86 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 12% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
공고 • Oct 29+ 1 more updateThe ACME Laboratories Ltd., Annual General Meeting, Dec 23, 2024The ACME Laboratories Ltd., Annual General Meeting, Dec 23, 2024, at 11:30 Central Asia Standard Time.
공고 • Oct 17The ACME Laboratories Ltd. to Report Fiscal Year 2024 Results on Oct 27, 2024The ACME Laboratories Ltd. announced that they will report fiscal year 2024 results on Oct 27, 2024
Reported Earnings • May 12Third quarter 2024 earnings released: EPS: ৳2.75 (vs ৳2.53 in 3Q 2023)Third quarter 2024 results: EPS: ৳2.75 (up from ৳2.53 in 3Q 2023). Revenue: ৳8.00b (up 22% from 3Q 2023). Net income: ৳582.3m (up 8.6% from 3Q 2023). Profit margin: 7.3% (down from 8.1% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
공고 • Apr 26The ACME Laboratories Ltd. to Report Q3, 2024 Results on Apr 29, 2024The ACME Laboratories Ltd. announced that they will report Q3, 2024 results on Apr 29, 2024
공고 • Jan 25The ACME Laboratories Ltd. to Report Q2, 2024 Results on Jan 30, 2024The ACME Laboratories Ltd. announced that they will report Q2, 2024 results on Jan 30, 2024
Upcoming Dividend • Nov 18Upcoming dividend of ৳3.30 per share at 3.5% yieldEligible shareholders must have bought the stock before 23 November 2023. Payment date: 17 January 2024. Payout ratio is a comfortable 29% but the company is not cash flow positive. Trailing yield: 3.5%. Within top quartile of Bangladeshi dividend payers (3.4%). Higher than average of industry peers (2.5%).
공고 • Nov 08The ACME Laboratories Ltd. to Report Q1, 2024 Results on Nov 13, 2023The ACME Laboratories Ltd. announced that they will report Q1, 2024 results on Nov 13, 2023
공고 • Oct 31The ACME Laboratories Ltd., Annual General Meeting, Dec 18, 2023The ACME Laboratories Ltd., Annual General Meeting, Dec 18, 2023, at 05:30 Coordinated Universal Time.
공고 • Oct 30The ACME Laboratories Ltd. Recommends Cash Dividend for the Year Ended June 30, 2023The Board of Directors of The ACME Laboratories Ltd. has recommended 33% cash dividend for the year ended June 30, 2023. Date of AGM December 18, 2023.
공고 • Oct 19The ACME Laboratories Ltd. to Report Fiscal Year 2023 Results on Oct 26, 2023The ACME Laboratories Ltd. announced that they will report fiscal year 2023 results on Oct 26, 2023
Reported Earnings • May 16Third quarter 2023 earnings released: EPS: ৳2.53 (vs ৳2.38 in 3Q 2022)Third quarter 2023 results: EPS: ৳2.53 (up from ৳2.38 in 3Q 2022). Revenue: ৳6.59b (up 8.8% from 3Q 2022). Net income: ৳536.3m (up 6.5% from 3Q 2022). Profit margin: 8.1% (down from 8.3% in 3Q 2022). The decrease in margin was driven by higher expenses.
Upcoming Dividend • Nov 16Upcoming dividend of ৳3.00 per shareEligible shareholders must have bought the stock before 21 November 2022. Payment date: 19 January 2023. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 3.5%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Higher than average of industry peers (2.5%).
공고 • Oct 28The ACME Laboratories Ltd. Recommends Cash Dividend for the Year Ended June 30, 2022The Board of Directors of The ACME Laboratories Ltd. has recommended 30% cash dividend for the year ended June 30, 2022. Date of AGM: December 20, 2022.
Reported Earnings • May 26Third quarter 2022 earnings released: EPS: ৳2.38 (vs ৳1.84 in 3Q 2021)Third quarter 2022 results: EPS: ৳2.38 (up from ৳1.84 in 3Q 2021). Revenue: ৳6.05b (up 16% from 3Q 2021). Net income: ৳503.7m (up 29% from 3Q 2021). Profit margin: 8.3% (up from 7.5% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 6% per year.
Reported Earnings • Feb 05Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: EPS: ৳2.40 (up from ৳1.78 in 2Q 2021). Revenue: ৳5.67b (up 13% from 2Q 2021). Net income: ৳507.1m (up 35% from 2Q 2021). Profit margin: 8.9% (up from 7.5% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Upcoming Dividend • Nov 14Upcoming dividend of ৳2.50 per shareEligible shareholders must have bought the stock before 21 November 2021. Payment date: 25 January 2022. Trailing yield: 2.8%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.7%).
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improved over the past weekAfter last week's 16% share price gain to ৳108, the stock trades at a trailing P/E ratio of 15.2x. Average trailing P/E is 29x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 36% over the past three years.
Valuation Update With 7 Day Price Move • Aug 09Investor sentiment improved over the past weekAfter last week's 15% share price gain to ৳88.10, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 13% over the past three years.
Reported Earnings • Apr 30Third quarter 2021 earnings released: EPS ৳1.84 (vs ৳1.68 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ৳5.23b (up 9.8% from 3Q 2020). Net income: ৳390.2m (up 10% from 3Q 2020). Profit margin: 7.5% (up from 7.4% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Feb 22New 90-day low: ৳67.60The company is down 1.0% from its price of ৳68.00 on 24 November 2020. The Bangladeshi market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 18% over the same period.
Reported Earnings • Jan 28Second quarter 2021 earnings released: EPS ৳1.78 (vs ৳1.77 in 2Q 2020)The company reported a mediocre second quarter result with weaker profit margins, although earnings were flat and revenues improved. Second quarter 2021 results: Revenue: ৳5.02b (up 7.7% from 2Q 2020). Net income: ৳377.1m (flat on 2Q 2020). Profit margin: 7.5% (down from 8.0% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Dec 28New 90-day high: ৳75.00The company is up 3.0% from its price of ৳72.70 on 29 September 2020. The Bangladeshi market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Nov 13New 90-day low: ৳68.00The company is down 1.0% from its price of ৳68.90 on 13 August 2020. The Bangladeshi market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period.
공고 • Oct 08The ACME Laboratories Ltd. to Report Fiscal Year 2020 Results on Oct 14, 2020The ACME Laboratories Ltd. announced that they will report fiscal year 2020 results on Oct 14, 2020